

Media Release

Zug, 1 June 2026

HBM Healthcare Investments Announces Closing of Swixx Biopharma Transaction with SK Capital and Bain Capital Life Sciences

HBM Healthcare Investments today announced the successful closing of the previously disclosed transaction, in which funds advised by SK Capital Partners and Bain Capital Life Sciences acquired a majority equity interest in Swixx Biopharma from HBM Healthcare Investments and certain other existing shareholders.

HBM Healthcare Investments will remain a significant shareholder of Swixx Biopharma with an equity ownership of approximately 8%, alongside the founders, senior management, SK Capital, Bain Capital Life Sciences, and Mérieux Equity Partners. The founders, HBM and Mérieux will also continue to serve actively on Swixx Biopharma's Board of Directors.

Swixx Biopharma has developed into a leading independent commercialization platform for innovative biopharmaceutical companies since its foundation in 2014, driven by strong organic growth, ongoing geographic expansion, and a scalable business model. With the support of its new shareholders, the company is well-positioned to accelerate its next phase of growth, further expand its geographic footprint, and continue to create long-term value.

HBM Healthcare Investments has been a shareholder of Swixx Biopharma since 2017, supporting the company through a period of significant growth and value creation. The investment has evolved into an exceptionally successful partnership and ranks as HBM's best-performing investment to date.

Contact

For further information, please contact Dr. Andreas Wicki on +41 41 710 75 77, or via e-mail at andreas.wicki@hbmhealthcare.com.

About HBM Healthcare Investments

HBM Healthcare Investments invests in the healthcare sector. The Company holds and manages an international portfolio of promising companies in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided in their strategic direction. This is what makes HBM Healthcare Investments an interesting alternative

to investments in big pharma and biotechnology companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

Disclaimer

The publication is for information purposes only and does not constitute an offer to sell or a solicitation to buy or subscribe for securities. This news release does not constitute a prospectus within the meaning of Art. 35ff FinSA, or securities prospectus in the sense of the German securities prospectus law. This news release and the information contained therein is not intended for distribution to the United States of America (USA) or within the USA and may not be distributed or forwarded to U.S. persons (including legal persons) or to publications with a general distribution in the USA. This news release is not an offer or solicitation to buy securities in the United States. HBM Healthcare Investments Ltd's securities were not issued in accordance with the U.S. securities laws, and may not be sold, offered for sale, or delivered in the U.S. or to U.S. individuals without prior registration or without a registration exemption. Some information quoted was obtained from external sources HBM considers to be reliable. HBM cannot guarantee the adequacy, accuracy, timeliness or completeness of or be held responsible or liable for errors of fact regarding such data and information obtained from third parties, and this data may change with market conditions. 08/20285